

### **Characterization of the genomic, cDNA and Amino Acid sequences of PILAR.**

The predicted Amino Acid sequence of the following genes encoding a C-type Lectin domain (Smart #00034; <http://smart.embl-heidelberg.de>) were aligned with ClustalW software (<http://www.ebi.ac.uk/clustalw/>) to create a pattern with the residues conserved in at least 6 of 9 sequences and coded by a single exon: AF097358, AF461811, AY486483, Z22576, AF175206, AY358499, DQ049594, HSA133532 and AF133299.

Genomic sequences at chromosome 12p12-13 were translated into the 6 possible ORFs by using ORF Finder software (<http://www.ncbi.nlm.nih.gov/gorf/gorf.html>) and were scanned for the presence of the pattern with PattenProt software ([http://npsa-pbil.ibcp.fr/cgi-bin/npsa\\_automat.pl?page=npsa\\_patinprot.html](http://npsa-pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=npsa_patinprot.html)).

RACE-PCR was performed with the human spleen marathon-ready cDNA kit (Clontech, Carlsbad, CA), following manufacturer's instructions. The following internal primers were used: Forward.Outer: 5'-CAGGGGACTGGCTTGGAGTGAGAGAT-3'; Forward.Inner: 5'-TCTGATGATACCAGAAATTGGACAGCCAGT-3'; Reverse.Outer: 5'-ATGGGCCCTCACCAGAGGTTCCGTAT-3'; Reverse.Inner: 5'-TGCTGCAAATCCAATTGATATCAATAAA-3'. The sequence was deposited at the Genbank (Accession#EF127467).

### **Real-Time Quantitative PCR.**

*PILAR* expression was analyzed by TaqMan PCR analysis as described previously (8, 22, 23). The *PILAR* system consisted of the following primers: *PILAR.F*, 5'-GTTAGCGCCTTGCCATGATTA -3', *PILAR.R*, 5'-AGGAAGCACATAAGGCCAATCTT -3'; and the probe *PILAR.P*, 5'-(FAM)CTTCATACATCGGATAGTTCCCAAGTTGATACA (TAMRA)-3'. We normalized the cDNA load to human *glyceraldehyde-3-phosphate dehydrogenase (GAPDH)* with primers *GAPDH F*: 5'-CCTGCACCACCAACTGCTTA -3' and *GAPDH R*: 5'-CATGAGTCCTTCCACGATACCA-3' and the probe *GAPDH.P*: 5'(FAM)CCTGGCCAAGGTCATCCATGACAAC(TAMRA)-3'.

### **Generation of soluble fusion proteins**

The cDNA that encodes the extracellular domain of CD161 (160 AA) was PCR amplified from mRNA isolated from human spleen using the primers *CD161.F*: aagcttATACAGAAATCATCAATAGAAAAATGC; and *CD161.R*: ggatccGAGTCAGGATACACTTTATTTCTCACA, which introduced restriction sequences for HindIII and BamHI. The fragment was subcloned into pSecTag (Invitrogen) in frame with a human Ig leader sequence (upstream) and a Myc epitope (downstream), followed by a 6 x His-tag, to generate the constructs Ig-*PILAR*-Myc and Ig-*CD161*-Myc. The sequence amplified with primers *BTN.F*: 5'-aagctTCAGTTTTCTGTGCTTGGAC-3' and *BTN.R*: 5'-gaattcTCTGGGCGCTCCTGAAGAAG-3', corresponding to the extracellular domain of *BTN3A1* (Genbank#NM\_007048) was cloned, expressed and purified in the same manner and used as a negative control.

293 cells were independently transfected with the plasmids pIg-*CD161*-Myc or pIg-*BTN*-Myc using Lipofectamine (Invitrogen), following manufacturer's instructions. Supernatants from the 2 transfections were harvested at day 3 and 7 and the secreted fusion proteins were purified from culture medium by using a standard Ni column (GE Healthcare), following manufacturer's instructions. After dialysis against PBS protein concentration determined by the Bradford assay.

### **ELISPOT analysis**

For ELISPOT analysis,  $2 \times 10^6$  PBMCs/ml from an A2<sup>+</sup> donor were incubated for 7 days (10:1) ratio with CEF peptide pool-pulsed (2  $\mu$ g/ml) A2<sup>+</sup> aAPCs or autologous monocyte-derived dendritic cells (generated by incubating magnetically purified CD14<sup>+</sup> cells for 7 days with Granulocyte–macrophage colony stimulating factor (20 ng/ml, Peprotech) and IL-4 (50 ng/ml, R&D)). Interferon- $\gamma$  ELISPOT was performed on day 8 against irradiated A2<sup>+</sup> aAPCs or autologous monocyte-derived dendritic cells (10:1 ratio), pulsed with 2  $\mu$ g/mL antigens.

Flat-bottomed, 96-well nitrocellulose-lined plates (Millipore MultiScreen, Millipore, Bedford, MA, USA) were coated with IFN- $\gamma$  mAb (MD-1; eBioscience, San Diego, CA) and incubated overnight at 4°C. After washing with Coating Buffer (eBioscience, San Diego, CA), plates were blocked with 10% FBS serum for 2 h at 37°C. Effector and target cells were incubated together for 20 h in RPMI medium 1640 supplemented with 10% FBS. After incubation, the plates were thoroughly washed with 0.05% Tween 20 in PBS to remove cells, and biotinylated secondary IFN- $\gamma$  mAb (4S.B3; eBioscience) was added to each well. After incubation for 2 h at 37°C, the plates were washed and developed with Avidin-horseradish peroxidase (eBioscience) for 1 h at room temperature. After washing, fresh substrate (3-amino-9-ethyl carbazole, Sigma, St. Louis, MO) was added and the plates incubated for approx. 20 min.

### **Nucleofection of T cells**

Unstimulated T cells were nucleofected using the Human T Cell Nucleofector Kit (Amaxa Inc., Gaithersburg, MD) and a pcDNA3.1 plasmid encoding the PILAR open-reading frame, following the manufacturer's protocol. Control lymphocytes were treated in an identical manner in the absence of the expression plasmid. Forty-eight hours post nucleofection the cells were stained for PILAR and analyzed by flow cytometry.